CD33 and acute myeloid leukemia: Gemtuzumab ozogamicin (ɑ-CD33) is a recombinant humanized IgG4κ antibody, which is conjugated to a cytotoxic antitumor antibiotic directed against the CD33 antigen present on leukemic myeloblasts in acute myeloid leukemia [19].